Praxis Precision Medicines, Inc. (PRAX) company profile
Close on Nov 17, 2026Market cap $8.52BP/E –Yield –
About Praxis Precision Medicines
Pharmaceutical Preparations, SIC 2834
The biopharmaceutical company specializes in developing precision therapies for central nervous system (CNS) disorders caused by imbalances in neuronal excitation and inhibition. Leveraging human genetic insights from epilepsies, the enterprise discovers and develops therapies using two proprietary platforms: Cerebrum, which focuses on small molecules, and Solidus, an antisense oligonucleotide engine. Its primary clinical-stage pipeline comprises small molecule candidates such as ulixacaltamide, vormatrigine, and relutrigine, as well as the oligonucleotide candidate elsunersen. The company creates these targeted therapeutics for individuals diagnosed with movement disorders, such as essential tremor, alongside severe genetic conditions like developmental and epileptic encephalopathies and common adult epilepsies.
The organization conducts clinical trials and development initiatives across diverse international territories by engaging a global network of contract research organizations and scientific collaborators. Additionally, the company maintains regional development and commercialization partnerships, including an agreement spanning China, Hong Kong, Macau, and Taiwan. The provided text does not disclose the location of the corporate headquarters.
Summary of the business section of Praxis Precision Medicines's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Praxis Precision Medicines, Inc.
- Headquarters
- Boston, MA
- Address
- 99 High Street, 30th Floor 02110
- Phone
- (617) 300-8460
- Website
- praxismedicines.com
- Employees
- 168, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- PRAX
- Exchange
- Nasdaq
- IPO date
- Oct 16, 2020
- Shares outstanding
- 28M, Jul 31, 2026
- Public float
- $883.20M, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-15 reverse, Nov 29, 2023
- SEC CIK
- 1689548
- CUSIP
- 74006W207
- ISIN
- US74006W2070
- FIGI
- BBG00W9LF2G5
- Share class FIGI
- BBG00W9LF2H4
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marcio Souza | Chief Executive Officer, Director | 56,495 |
| Timothy Edwin Kelly | Chief Financial Officer | 31,167 |
| Megan Sniecinski | Chief Operating Officer | 28,664 |
| Lauren Mastrocola | Principal Accounting Officer | 13,573 |
| Alex Nemiroff | General Counsel and Secretary | 26,011 |
| Jill DeSimone | Director | 13,807 |
| Merit Ester Cudkowicz | Director | 1,371 |
| Jeffrey B. Kindler | Director | 2,537 |
| William D. Young | Director | 3,269 |
| Stuart A. Arbuckle | Director | 2,537 |
| Gregory Norden | Director | 1,559 |
| Dean J. Mitchell | Director | 18,622 |
| Jeffrey Chodakewitz | Director | 1,371 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $8.71M | $55.53M | $3.02M | $36 | $125 |
| FY2024 | $13.43M | $20.64M | $3.98M | $9 | $93 |
| FY2023 | $2.12M | $1.40M | $933.45K | $3 | $94 |
| FY2022 | $6.03M | -$17.64M | $2.45M | $4 | $90 |
| FY2021 | $10.91M | -$62.15M | $4.12M | $36 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Marcio Souza President and Chief Executive Officer | $659.20K | $2.37M | $3.69M | $1.48M | $507.00K | $8.71M | -35% |
| Timothy Kelly Chief Financial Officer | $526.85K | $789.38K | $1.23M | $632.22K | $22.38K | $3.20M | -21% |
| Alex Nemiroff General Counsel | $456.23K | $710.44K | $1.11M | $547.47K | $22.31K | $2.84M | -27% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 16, 2020
- Offer price
- $19.00
- Securities offered
- 10,000,000
- Gross proceeds
- $190.00M
- Exchange
- Nasdaq
- First trading day
- Oct 16, 2020
- First-day close
- $27.80+46.3%
- Lock-up ends (est.)
- Apr 14, 2021
“Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “PRAX.” The initial public offering price of our common stock is $19.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 16, 2026, we have 168 employees and plan to continue to grow as we advance the potential of our pipeline.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 2, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 16, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 14, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?